Literature DB >> 1929312

Effects of enzyme supplementation on oral absorption of ciprofloxacin in patients with cystic fibrosis.

G Mack1, P J Cooper, N Buchanan.   

Abstract

The effect of pancreatic enzyme supplementation on the absorption of an oral dose of 250 mg of ciprofloxacin was studied in six patients with cystic fibrosis in a crossover design. The time to achieve maximum serum concentration was slightly reduced upon coadministration of pancreatic enzymes. There were no significant differences in peak concentration, elimination half-life, and area under the concentration-time curve.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929312      PMCID: PMC245195          DOI: 10.1128/AAC.35.7.1484

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Reduced enteral absorption of ciprofloxacin in the presence of antacids.

Authors:  G Höffken; K Borner; P D Glatzel; P Koeppe; H Lode
Journal:  Eur J Clin Microbiol       Date:  1985-06       Impact factor: 3.267

2.  Determination of ciprofloxacin in biological samples by reversed-phase high performance liquid chromatography.

Authors:  F Vallée; M LeBel; M G Bergeron
Journal:  Ther Drug Monit       Date:  1986       Impact factor: 3.681

3.  Pharmacokinetics of ciprofloxacin in cystic fibrosis.

Authors:  R L Davis; J R Koup; J Williams-Warren; A Weber; L Heggen; D Stempel; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

4.  Patients, clinicians, and the science of investigation.

Authors:  A Soffer
Journal:  Chest       Date:  1985-09       Impact factor: 9.410

5.  Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis.

Authors:  J A Bosso; P G Black; J M Matsen
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

6.  Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis.

Authors:  M E Hodson; C M Roberts; R J Butland; M J Smith; J C Batten
Journal:  Lancet       Date:  1987-01-31       Impact factor: 79.321

7.  Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis.

Authors:  J Goldfarb; G P Wormser; M A Inchiosa; G Guideri; M Diaz; R Gandhi; C Goltzman; A V Mascia
Journal:  J Clin Pharmacol       Date:  1986-03       Impact factor: 3.126

8.  The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin.

Authors:  D C Brittain; B E Scully; M J McElrath; R Steinman; P Labthavikul; H C Neu
Journal:  J Clin Pharmacol       Date:  1985-03       Impact factor: 3.126

9.  Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis.

Authors:  M D Reed; R C Stern; C M Myers; T S Yamashita; J L Blumer
Journal:  J Clin Pharmacol       Date:  1988-08       Impact factor: 3.126

10.  High-performance liquid chromatography of ciprofloxacin and its metabolites in serum, urine and sputum.

Authors:  C M Myers; J L Blumer
Journal:  J Chromatogr       Date:  1987-11-27
  10 in total
  2 in total

Review 1.  Oral anti-pseudomonal antibiotics for cystic fibrosis.

Authors:  Tracey Remmington; Nikki Jahnke; Christian Harkensee
Journal:  Cochrane Database Syst Rev       Date:  2016-07-14

2.  Pancreatic enzyme replacement therapy for people with cystic fibrosis.

Authors:  Usha Rani R Somaraju; Arturo Solis-Moya
Journal:  Cochrane Database Syst Rev       Date:  2020-08-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.